FreeCME

Patient Perspectives and Clinical Updates on Somatostatin Receptor-Positive Neuroendocrine Tumors

CME: 1.0

October 18, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

The intended audience for this activity program are medical oncologists, endocrinologists, radiation oncologists, nuclear-medicine physicians and technologists, surgical oncologists, interventional radiologists, internists, nurses, nurse practitioners, and physician assistants managing patients with NETs.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the clinical characteristics and key aspects of a diagnosis of GEP-NETs
  • Discuss the rationale for using somatostatin analogues and PRRTs
  • Evaluate practice-changing clinical-trial data on the efficacy and safety of somatostatin analogues and PRRT
  • Implement strategies to minimize adverse events and improve outcomes for patients with somatostatin-positive NETs
  • Optimize patient-centered management by integrating suggestions from real-world patient perspectives into treatments

Post a comment to this article